<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The frequency of <z:mp ids='MP_0011356'>RAS</z:mp> activation was studied in 48 patients with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) or with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), in order to address the question of whether patients possessing <z:mp ids='MP_0004026'>monosomy</z:mp> 7 or other alterations of chromosome 7 have a higher incidence of <z:mp ids='MP_0011356'>RAS</z:mp> activation than those lacking chromosome 7 abnormalities </plain></SENT>
<SENT sid="1" pm="."><plain>Samples were screened for oncogenic point mutation by DNA amplification followed by oligonucleotide hybridization analysis at codons 12, 13 and 61 of N-<z:mp ids='MP_0011356'>RAS</z:mp> and codons 12 and 13 of K-<z:mp ids='MP_0011356'>RAS</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>Two additional samples were considered to have activated <z:mp ids='MP_0011356'>RAS</z:mp> due to additional karyotypic abnormalities t(5;12) or loss of both copies of chromosome 17 and hence, the <z:hpo ids='HP_0001067'>neurofibromatosis</z:hpo> (NF1) loci </plain></SENT>
<SENT sid="3" pm="."><plain>The group of <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_501'>myelomonocytic leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) patients had activated <z:mp ids='MP_0011356'>RAS</z:mp> in 4/11 cases and inclusion of two CMMLt patients (with <z:mp ids='MP_0004026'>monosomy</z:mp> 7) brings this incidence to 5/13 </plain></SENT>
<SENT sid="4" pm="."><plain>No change in frequency of <z:mp ids='MP_0011356'>RAS</z:mp> activation was seen between groups containing de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> samples with or without chromosome 7 abnormalities (1/5 and 2/12, respectively) </plain></SENT>
<SENT sid="5" pm="."><plain>However, assessment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> samples in the process of, or subsequent to, leukaemic progression showed a difference between the two groups </plain></SENT>
<SENT sid="6" pm="."><plain>The frequency of <z:mp ids='MP_0011356'>RAS</z:mp> activation in samples with <z:mp ids='MP_0004026'>monosomy</z:mp> 7 was 4/9 samples while none of the seven samples without chromosome 7 changes showed <z:mp ids='MP_0011356'>RAS</z:mp> activation </plain></SENT>
<SENT sid="7" pm="."><plain>The co-existence of <z:mp ids='MP_0011356'>RAS</z:mp> activation and <z:mp ids='MP_0004026'>monosomy</z:mp> 7 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> indicates that these lesions can co-operate in the multistep process of <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">leukemogenesis</z:e> </plain></SENT>
</text></document>